TheraRadar
Data updated: May 26, 2026

PARLODEL (bromocriptine mesylate)

CNS Approved 1978-06-28

PARLODEL is indicated for the treatment of Hyperprolactinemia; Amenorrhea; Galactorrhea; Infertility; Hypogonadism; Prolactin-Secreting Adenoma; Acromegaly; Parkinson's Disease.

Source: FDA Label • ESJAY PHARMA

How PARLODEL Works

Bromocriptine is a semi-synthetic ergot alkaloid that acts as a potent dopamine D2 receptor agonist and a partial D1 receptor antagonist. It inhibits the secretion of prolactin from the anterior pituitary by stimulating D2 receptors on lactotroph cells. In patients with acromegaly, it paradoxically suppresses the release of growth hormone. In the treatment of Parkinson’s disease, bromocriptine directly stimulates postsynaptic dopamine receptors in the corpus striatum, helping to compensate for the deficiency of endogenous dopamine.

2
Indications
--
Phase 3 Trials
1
Priority Reviews
47
Years on Market

Details

Status
Prescription
First Approved
1978-06-28
Routes
ORAL
Dosage Forms
TABLET, CAPSULE

Companies

Active Ingredient: BROMOCRIPTINE MESYLATE

PARLODEL Approval History

1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
134 FDA actions from 1978 to 2021 · 1 indication expansions
Jul 2021 SUPPL
Label · Labeling
Dec 2019 SUPPL
Label · Labeling
Jun 2016 SUPPL Priority
Mfg · Manufacturing (CMC)

What PARLODEL Treats

8 indications

PARLODEL is approved for 8 conditions since its original approval in 1978. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hyperprolactinemia
  • Amenorrhea
  • Galactorrhea
  • Infertility
  • Hypogonadism
  • Prolactin-Secreting Adenoma
  • Acromegaly
  • Parkinson's Disease
Source: FDA Label

PARLODEL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to PARLODEL

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ANDROGEL
TESTOSTERONE
1 shared
BESINS HLTHCARE
Shared indications:
AVEED
TESTOSTERONE UNDECANOATE
1 shared
ENDO OPERATIONS
Shared indications:
AZILECT
RASAGILINE MESYLATE
1 shared
Teva
Shared indications:
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT02078440 VS-PEDS BA-2010 Ph 1 completed Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PARLODEL FDA Label Details

Indications & Usage

FDA Label (PDF)

PARLODEL is indicated for the treatment of Hyperprolactinemia; Amenorrhea; Galactorrhea; Infertility; Hypogonadism; Prolactin-Secreting Adenoma; Acromegaly; Parkinson's Disease.

Track PARLODEL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.